HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces that it is expanding its pipeline in neurodegenerative conditions for COYA 302 beyond ALS to include frontotemporal dementia (FTD) and Parkinson’s disease (PD).

休斯顿--（商业新闻短讯）--Coya Therapeutics，Inc.（纳斯达克：Coya）（“Coya”或“公司”）是一家临床阶段的生物技术公司，开发旨在增强Treg功能的生物制剂，宣布正在扩大Coya 302神经退行性疾病的管道，使其超越ALS，包括额颞叶痴呆（FTD）和帕金森病（PD）。

The Company’s updated pipeline can be viewed here..

可以在此处查看公司更新的管道。。

FTD and PD share a similar disease pathogenesis to ALS that is associated with a heightened proinflammatory cascade involving dysfunctional Tregs and proinflammatory microglia and macrophages. The biological redundancies in molecular immune pathways in these complex diseases limit the efficacy of many single drug therapies, requiring the development of novel therapeutics that can address this pathophysiologic complexity..

FTD和PD与ALS具有相似的疾病发病机制，这与涉及功能失调的Tregs和促炎性小胶质细胞和巨噬细胞的促炎级联反应增强有关。这些复杂疾病中分子免疫途径的生物学冗余限制了许多单一药物疗法的疗效，需要开发能够解决这种病理生理复杂性的新型疗法。。

Dr. Fred Grossman, Coya’s President and Chief Medical Officer stated, “ALS, FTD, and PD are driven by a similar, yet complex, proinflammatory environment that requires targeting more than a single pathway. COYA 302 has been designed to target multiple pathways, such as restoring dysfunctional Tregs and inhibiting proinflammatory microglia and macrophages, and may have disease modifying potential in these severe diseases with high unmet need.”.

Coya总裁兼首席医疗官Fred Grossman博士表示，“ALS，FTD和PD是由类似但复杂的促炎环境驱动的，需要靶向不止一种途径。COYA 302被设计用于靶向多种途径，例如恢复功能失调的Tregs和抑制促炎性小胶质细胞和巨噬细胞，并且可能在这些严重疾病中具有改善疾病的潜力，这些疾病的需求尚未得到满足。”。

COYA 302 is a dual-mechanism investigational biologic combination immunotherapy comprised of proprietary low dose IL-2 and fusion protein CTLA-4 Ig. Low dose IL-2 enhances anti-inflammatory Treg function and numbers while the fusion protein CTLA-4 Ig suppress proinflammatory cell function, enabling potentially synergistic mechanisms in modulating inflammatory pathways and restoring immune balance.

COYA 302是一种双机制研究性生物联合免疫疗法，由专有的低剂量IL-2和融合蛋白CTLA-4 Ig组成。低剂量IL-2增强抗炎Treg功能和数量，而融合蛋白CTLA-4 Ig抑制促炎细胞功能，从而在调节炎症途径和恢复免疫平衡方面实现潜在的协同机制。

COYA 302 has the potential to be disease modifying by targeting multiple dysregulated immune pathways while restoring function in anti-inflammatory Treg function..

COYA 302有可能通过靶向多种失调的免疫途径来改善疾病，同时恢复抗炎Treg功能。。

Coya intends to file an IND for COYA 302 for the treatment of ALS in the first half of 2024 and an IND for COYA 302 for the treatment of FTD before the end of 2024. In addition, studies in animal models of PD are planned in 2024, and based on those studies, a subsequent IND filing is anticipated for the treatment of PD..

Coya打算在2024年上半年为Coya 302提交一份IND，用于治疗ALS，并在2024年底之前为Coya 302提交一份IND，用于治疗FTD。此外，计划于2024年对PD动物模型进行研究，并根据这些研究，预计随后的IND申请将用于治疗PD。。

Howard H. Berman, Ph.D., Coya’s CEO stated: “Our vision has always been to leverage the potential of Tregs in neurodegenerative diseases. With COYA 302, we have taken a page from the playbook of oncology and viral disease where combination therapies have been transformational. We believe that the complementary and possibly synergistic multi-mechanism mode of action of COYA 302 in targeting the complex immune environment will lead to promising clinical outcomes in patients with neurodegenerative diseases.”.

霍华德·H·伯曼博士。，Coya首席执行官表示：“我们的愿景一直是利用Tregs在神经退行性疾病中的潜力。有了COYA 302，我们从肿瘤学和病毒性疾病的剧本中翻开了一页，联合疗法已经发生了转变。我们相信COYA 302在针对复杂免疫环境方面的互补和可能协同的多机制作用模式将导致prom改善神经退行性疾病患者的临床结果。”。

The Company also announces its key milestones and catalysts anticipated in 2024, including:

该公司还宣布了2024年的关键里程碑和催化剂，包括：

H1 2024:

2024年上半年：

COYA 302 File IND and Initiate Phase 2 Trial in ALS Patients

COYA 302文件IND并启动ALS患者的2期试验

COYA 302 Publication of Phase 1 Investigator Initiated Trial clinical data in ALS Patients

COYA 302发布ALS患者的第一阶段研究者启动的试验临床数据

COYA 302 Publication of Longitudinal Biomarker study with correlation to patient survival in ALS Patients

COYA 302发表与ALS患者生存相关的纵向生物标志物研究

COYA 302 Presentation on Longitudinal Biomarker Data in ALS Patients at Conference

COYA 302在会议上介绍ALS患者的纵向生物标志物数据

COYA 301 Presentation of Phase 1 Investigator Initiated Trial data in AD Patients at 18th annual AD + PD Conference

COYA 301在第18届AD+PD年度会议上介绍AD患者的第一阶段研究者启动的试验数据

H2 2024:

2024年下半年：

COYA 302 First patient dosed in Phase 2 Trial in ALS Patients

COYA 302首次在ALS患者的2期试验中给药

COYA 302 File IND and Initiate Phase 2 Trial in FTD Patients

COYA 302文件IND并启动FTD患者的2期试验

COYA 302 Animal data released in PD model

在PD模型中发布的COYA 302动物数据

COYA 301 Proof of Concept combination data with Drug X in AD mouse model

COYA 301在AD小鼠模型中与药物X的概念验证组合数据

COYA 301 Phase 2 Investigator Initiated Trial Topline AD data Presented (Summer)

COYA 301第二阶段调查员启动的试验Topline AD数据（夏季）

About COYA 302

关于COYA 302

COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 is comprised of proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being developed for subcutaneous administration for the treatment of patients with ALS.

COYA 302是一种研究性和专有的生物联合疗法，具有双重免疫调节作用机制，旨在增强调节性T细胞（Tregs）的抗炎功能并抑制活化的单核细胞和巨噬细胞产生的炎症。COYA 302由专有的低剂量白细胞介素-2（LD IL-2）和CTLA-4 Ig组成，正在开发用于皮下给药以治疗ALS患者。

These mechanisms may have additive or synergistic effects..

这些机制可能具有累加或协同效应。。

In February of 2023, Coya announced results from a proof-of-concept, open-label clinical study evaluating LD IL-2 and CTLA-4 Ig in a small cohort of patients with ALS conducted at the Houston Methodist Research Institute (Houston, Texas) by Stanley Appel, M.D., Jason Thonhoff, M.D., Ph.D., and David Beers, Ph.D.

2023年2月，Coya宣布了由Stanley Appel，M.D.，Jason Thonhoff，M.D.，Ph.D。和David Beers，Ph.D.在休斯顿卫理公会研究所（德克萨斯州休斯顿）进行的一小群ALS患者中评估LD IL-2和CTLA-4 Ig的概念验证，开放标签临床研究的结果。

This study was the first-of-its-kind evaluating this dual-mechanism immunotherapy for the treatment of ALS. Patients in the study received investigational treatment for 48 consecutive weeks and were evaluated for safety and tolerability, Treg function, serum biomarkers of oxidative stress and inflammation, and clinical functioning as measured by the ALSFRS-R scale..

这项研究是首次评估这种用于治疗ALS的双重机制免疫疗法。该研究中的患者连续48周接受研究性治疗，并通过ALSFRS-R量表评估其安全性和耐受性，Treg功能，氧化应激和炎症的血清生物标志物以及临床功能。。

During the 48-week treatment period, the therapy was well tolerated. The most common adverse event was mild injection-site reactions. No patient discontinued the study, and no deaths or other serious adverse events were reported.

在48周的治疗期间，治疗耐受性良好。最常见的不良事件是轻微的注射部位反应。没有患者停止研究，也没有死亡或其他严重不良事件的报告。

Patients' disease progression was measured using the ALSFRS-R scale, a validated rating tool for monitoring the progression of disability in patients with ALS. The mean (±SD) ALSFRS-R scores at week 24 (33.75 ±3.3) and week 48 (32 ±7.8) after initiation of treatment were not statistically different compared to the ALSFRS-R score at baseline (33.5 ±5.9), suggesting significant amelioration in the progression of the disease over the 48-week treatment period..

使用ALSFRS-R量表测量患者的疾病进展，ALSFRS-R量表是一种经过验证的评估工具，用于监测ALS患者的残疾进展。治疗开始后第24周（33.75±3.3）和第48周（32±7.8）的平均（±SD）ALSFRS-R评分与基线时的ALSFRS-R评分（33.5±5.9）相比无统计学差异，表明48周治疗期间疾病进展显着改善。。

Treg suppressive function, expressed as percentage of inhibition of proinflammatory T cell proliferation, showed a statistically significant increase over the course of the treatment period and was significantly reduced at the end of the 8-week washout post-treatment period. Treg suppressive function at 24 weeks (79.9 ±9.6) and 48 weeks (89.5 ±4.1) were significantly higher compared to baseline (62.1 ±8.1) (p<0.01), suggesting enhanced and durable Treg suppressive function over the course of treatment.

Treg抑制功能表示为促炎性T细胞增殖抑制的百分比，在治疗期间显示出统计学上显着的增加，并且在治疗后8周的清除期结束时显着降低。24周（79.9±9.6）和48周（89.5±4.1）的Treg抑制功能明显高于基线（62.1±8.1）（p＜0.01），表明治疗过程中Treg抑制功能增强且持久。

In contrast, Treg suppressive function (mean ±SD) was significantly decreased at the end of the 8-week washout period compared to end-of-treatment at week 48 (70.3 ±8.1 vs. 89.5 ±4.1, p <0.05)..

相比之下，与第48周治疗结束时相比，8周清除期结束时Treg抑制功能（平均值±SD）显着降低（70.3±8.1比89.5±4.1，p＜0.05）。。

The study also evaluated serum biomarkers of inflammation, oxidative stress, and lipid peroxides. The available data up to 16 weeks after initiation of treatment suggest a decrease in these biomarker levels, which is consistent with the observed enhancement of Treg function. The evaluation of the full biomarker data is ongoing..

该研究还评估了炎症，氧化应激和脂质过氧化物的血清生物标志物。治疗开始后16周的可用数据表明这些生物标志物水平降低，这与观察到的Treg功能增强一致。正在对完整的生物标志物数据进行评估。。

COYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency.

COYA 302是一种尚未获得FDA或任何其他监管机构批准的研究产品。

About Amyotrophic Lateral Sclerosis

关于肌萎缩侧索硬化症

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons, the nerve cells in the brain and spinal cord that control voluntary muscle movement. About 20,000 people live with ALS in the United States and approximately 5,000 new cases are diagnosed every year.

肌萎缩侧索硬化症（ALS），也称为Lou Gehrig病，是一种罕见的神经系统疾病，会影响运动神经元，即大脑和脊髓中控制自主肌肉运动的神经细胞。在美国，大约有20000人患有ALS，每年大约有5000例新病例被诊断出来。

The disease is progressive, meaning the symptoms get worse over time. The functional status of ALS patients declines about 1 point per month on average, as measured by the Revised ALS Function Rating Scale1, or ALSFRS-R, a validated tool to monitor the progression of the disease..

这种疾病是进行性的，意味着症状会随着时间的推移而恶化。ALS患者的功能状态平均每月下降约1分，这是通过修订的ALS功能评定量表1或ALSFRS-R（一种经过验证的监测疾病进展的工具）来衡量的。。

ALS has no cure, and the currently approved drug treatments provide limited benefit to patients. ALS is a type of motor neuron disease. As motor neurons degenerate and die, they stop sending messages to the muscles, which causes the muscles to weaken, start to twitch (fasciculations), and waste away (atrophy).

ALS无法治愈，目前批准的药物治疗对患者的益处有限。ALS是一种运动神经元疾病。当运动神经元退化并死亡时，它们停止向肌肉发送信息，这会导致肌肉衰弱，开始抽搐（束缚），并消耗（萎缩）。

Eventually, the brain loses its ability to initiate and control voluntary movements. Most people with ALS die from respiratory failure, usually within three to five years from when the symptoms first appear.2.

最终，大脑失去了启动和控制自主运动的能力。大多数ALS患者死于呼吸衰竭，通常在症状首次出现后的三到五年内。

About Frontotemporal Dementia

关于额颞叶痴呆

Frontotemporal dementia (FTD) is the result of damage to neurons in the frontal and temporal lobes of the brain. Many possible symptoms can result, including unusual behaviors, emotional problems, trouble communicating, difficulty with work, or difficulty with walking. FTD is rare and tends to occur at a younger age than other forms of dementia.

额颞叶痴呆（FTD）是大脑额叶和颞叶神经元受损的结果。可能导致许多可能的症状，包括异常行为、情绪问题、沟通困难、工作困难或行走困难。FTD很少见，并且比其他形式的痴呆症更容易发生在年轻的年龄。

About 60% of people with FTD are 45 to 64 years old. FTD is progressive, meaning symptoms get worse over time. In the early stages, people may have just one symptom. As the disease progresses, other symptoms appear as more parts of the brain are affected. It is difficult to predict how long someone with FTD will live.

大约60%的FTD患者年龄在45至64岁之间。FTD是进行性的，意味着症状会随着时间的推移而恶化。在早期阶段，人们可能只有一种症状。随着疾病的进展，随着大脑更多部位受到影响，还会出现其他症状。很难预测患有FTD的人会活多久。

Some people live more than 10 years after diagnosis, while others live less than two years after they are diagnosed. There is no cure for FTD, and no treatments slow or stop the progression of the disease.3.

一些人在确诊后活了10年以上，而另一些人在确诊后活不到两年。FTD无法治愈，也没有任何治疗方法可以减缓或阻止疾病的进展。

About Parkinson’s Disease

关于帕金森氏病

Parkinson’s disease (PD) is a progressive brain disorder that causes unintended or uncontrollable movements, such as shaking, stiffness, and difficulty with balance and coordination. The most prominent manifestations of PD occur when nerve cells in the basal ganglia, an area of the brain that controls movement, become impaired or die.

帕金森氏病（PD）是一种进行性脑部疾病，会导致意外或无法控制的运动，例如颤抖，僵硬以及平衡和协调困难。PD最突出的表现发生在基底神经节（大脑中控制运动的区域）的神经细胞受损或死亡时。

As the disease progresses, people may have difficulty walking and talking. They may also have mental and behavioral changes, sleep problems, depression, memory difficulties, and fatigue. Most people with PD first develop the disease after age 60, but about 10% experience onset before the age of 50. There is no cure for PD, and currently available treatments are intended to relieve some symptoms.4.

随着疾病的进展，人们可能难以行走和说话。他们也可能有心理和行为改变，睡眠问题，抑郁，记忆困难和疲劳。大多数PD患者在60岁后首次发病，但约10%的人在50岁之前发病。PD尚无治愈方法，目前可用的治疗方法旨在缓解某些症状。

References

参考文献

Atassi N, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology, 2014;83:1719–1725. doi: 10.1212/WNL.0000000000000951.

Atassi N等人。PRO-ACT数据库：设计，初步分析和预测特征。神经病学，2014；83:1719-1725。doi:10.1212/WNL.0000000000000951。

National Institutes of Health (NIH) Website (https://www.ninds.nih.gov), accessed on January 8, 2024.

美国国立卫生研究院（NIH）网站(https://www.ninds.nih.gov)，于2024年1月8日访问。

National Institutes of Health (NIH) Website (https://www.nia.nih.gov), accessed on January 8, 2024.

美国国立卫生研究院（NIH）网站(https://www.nia.nih.gov)，于2024年1月8日访问。

National Institutes of Health (NIH) Website (https://www.nia.nih.gov), accessed on January 8, 2024.

美国国立卫生研究院（NIH）网站(https://www.nia.nih.gov)，于2024年1月8日访问。

About Coya Therapeutics, Inc.

关于Coya Therapeutics，Inc。

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system..

Coya Therapeutics，Inc.（纳斯达克股票代码：Coya）总部位于德克萨斯州休斯顿，是一家临床阶段生物技术公司，开发专有治疗方法，专注于调节性T细胞（“Tregs”）的生物学和潜在治疗优势，以靶向全身炎症和神经炎症。功能失调的Tregs是许多疾病的基础，包括神经退行性疾病，代谢性疾病和自身免疫性疾病，这种细胞功能障碍可能导致持续的炎症和氧化应激，导致免疫系统缺乏稳态。。

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers.

Coya的研究产品候选管道利用多种治疗方式，旨在恢复Tregs的抗炎和免疫调节功能。Coya的治疗平台包括Treg增强生物制剂，Treg衍生的外泌体和自体Treg细胞疗法。Coya的300系列候选产品Coya 301和Coya 302是旨在增强Treg功能和扩大Treg数量的生物疗法。

COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo. COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages.

COYA 301是一种用于皮下给药的细胞因子生物制剂，旨在增强Treg功能并扩大体内Treg数量。COYA 302是一种用于皮下和/或静脉内给药的生物组合，旨在增强Treg功能，同时消耗T效应子功能和活化的巨噬细胞。

These two mechanisms may be additive or synergistic in suppressing inflammation. For more information about Coya, please visit www.coyatherapeutics.com..

这两种机制在抑制炎症方面可能是相加的或协同的。有关Coya的更多信息，请访问www.coyatherapeutics.com。。

Forward-Looking Statements

前瞻性声明

This press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities.

本新闻稿包含基于管理层的信念和假设以及管理层目前可获得的信息的“前瞻性”声明。前瞻性陈述包括除本演示文稿中包含的历史事实陈述以外的所有陈述，包括有关我们当前和未来财务业绩、业务计划和目标、当前和未来临床和临床前开发活动、我们正在进行和计划中的临床试验的时间和成功以及相关数据的信息，我们临床试验和相关数据的发布时间、更新和结果，我们获得和维持监管批准的能力，我们候选产品的潜在治疗效益和经济价值，竞争地位，行业环境和潜在市场机会。

The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements..

“相信”、“可能”、“会”、“估计”、“继续”、“预期”、“打算”、“预期”等词语以及类似的表达旨在识别前瞻性陈述。。

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue, capital .

前瞻性陈述受到已知和未知风险、不确定性、假设和其他因素的影响，包括但不限于与新型冠状病毒影响相关的风险；我们的产品候选开发活动以及正在进行和计划进行的临床试验的成功，成本和时间安排；我们计划开发和商业化靶向治疗药物；我们的临床前或临床试验中患者登记和给药的进展；我们的候选产品在临床试验中达到适用终点的能力；我们候选产品的安全概况；我们的临床试验数据支持营销应用的潜力，以及这些事件的时间安排；我们获得运营资金的能力；我们候选产品的开发和商业化；获得和维持监管批准的时间和能力；我们候选产品的市场接受率和程度以及临床实用性；我们候选产品的市场规模和增长潜力，以及我们服务这些市场的能力；我们的商业化、营销和制造能力和战略；与第三方就我们候选产品的商业化达成的未来协议；我们对获得和维持知识产权保护能力的期望；我们对第三方制造商的依赖；已经或可能获得的竞争疗法或产品的成功；我们吸引和留住关键科学或管理人员的能力；我们能够确定与我们的商业目标一致的具有重大商业潜力的其他候选产品；以及我们对费用、未来收入和资本的估计。

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs.

我们的这些前瞻性陈述主要基于我们目前对未来事件和趋势的预期和预测，我们认为这些事件和趋势可能会影响我们的财务状况、运营结果、业务战略、短期和长期业务运营和目标以及财务需求。

Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

此外，我们的经营环境竞争激烈，变化迅速，新的风险可能会不时出现。我们的管理层不可能预测所有风险，也不可能评估所有因素对我们业务的影响，也不可能评估任何因素或因素组合可能导致实际结果与我们可能做出的任何前瞻性陈述中所包含的结果存在重大差异的程度。

In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or will occur.

鉴于这些风险、不确定性和假设，本文讨论的前瞻性事件和情况可能不会发生，实际结果可能与前瞻性声明中预期或暗示的结果存在重大不利差异。虽然我们的管理层认为我们的前瞻性声明中反映的期望是合理的，但我们不能保证前瞻性声明中描述的未来结果、活动水平、绩效或事件和情况会实现或发生。

We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise..

我们没有义务公开更新任何前瞻性声明，无论是书面的还是口头的，无论是由于新信息、未来发展还是其他原因。。